Conceptus 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Date of Report (Date of earliest event reported): February 24, 2005
(Exact name of registrant as specified in charter)
1021 Howard Avenue
San Carlos, CA 94070
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code: (650) 628-4700
o Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On February 24, 2005, Conceptus Inc. issued a press release announcing that it has submitted a Pre-Market Approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) in order to extend effectiveness data on the Essure product labeling. A copy of the press release is attached as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.